<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>03573026624750</udiDi>
    <basicUdiDi>357302BUDI000834U3</basicUdiDi>
    <tradeName>ETEST® ESBL Cefepime/cefepime + clavulanic acid (PM/PML)</tradeName>
    <deviceName>ETEST® ESBL Cefepime/cefepime + clavulanic acid (PM/PML)</deviceName>
    <manufacturerName>bioMérieux SA</manufacturerName>
    <manufacturerSrn>FR-MF-000004436</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf B</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0104080505</emdnCode>
    <emdnDescription>TARGETED RESISTANCE TESTS - ESBL</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>543022</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-30T18:00:01.127Z</lastUpdated>
  </row>
  <row>
    <udiDi>03573026624736</udiDi>
    <basicUdiDi>357302BUDI000826U4</basicUdiDi>
    <tradeName>ETEST® ESBL Cefotaxime/cefotaxime + clavulanic acid (CT/CTL)</tradeName>
    <deviceName>ETEST® ESBL Cefotaxime/cefotaxime + clavulanic acid (CT/CTL)</deviceName>
    <manufacturerName>bioMérieux SA</manufacturerName>
    <manufacturerSrn>FR-MF-000004436</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf B</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0104080505</emdnCode>
    <emdnDescription>TARGETED RESISTANCE TESTS - ESBL</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>543020</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-30T17:59:58.710Z</lastUpdated>
  </row>
  <row>
    <udiDi>03573026624712</udiDi>
    <basicUdiDi>357302BUDI000828U8</basicUdiDi>
    <tradeName>ETEST® ESBL Ceftazidime/ceftazidime + clavulanic acid (TZ/TZL)</tradeName>
    <deviceName>ETEST® ESBL Ceftazidime/ceftazidime + clavulanic acid (TZ/TZL)</deviceName>
    <manufacturerName>bioMérieux SA</manufacturerName>
    <manufacturerSrn>FR-MF-000004436</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf B</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0104080505</emdnCode>
    <emdnDescription>TARGETED RESISTANCE TESTS - ESBL</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>542962</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-30T17:59:57.125Z</lastUpdated>
  </row>
  <row>
    <udiDi>16972698601221</udiDi>
    <basicUdiDi>B-16972698601221</basicUdiDi>
    <tradeName>CTX-M β-lactamases Rapid Test</tradeName>
    <deviceName>CTX-M β-lactamases Rapid Test</deviceName>
    <manufacturerName>Hangzhou Genesis Biodetection and Biocontrol Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013495</manufacturerSrn>
    <authorisedRepresentativeName>CMC Medical Devices &amp; Drugs SL</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000000293</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W0104080505</emdnCode>
    <emdnDescription>TARGETED RESISTANCE TESTS - ESBL</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P261104</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-11T06:52:01.921Z</lastUpdated>
  </row>
</eudamedExport>